INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Karyopharm and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

On July 17, 2026, Karyopharm disclosed in a filing with the U.S. Securities and Exchange Commission the implementation of “a retention program for certain employees of the Company, including each of the Company’s named executive officers and the Chief Financial Officer”, under which top Karyopharm executives will receive “lump sum cash retention awards” ranging from $625,000 to $1,725,000.

On this news, Karyopharm’s stock price fell $2.04 per share, or 21.45%, to close at $7.47 per share on July 20, 2026.